Cold Spring Harbor Laboratory this week announced that it is working with Pfizer to develop a next-generation library of human shRNAs to assist with the identification of new cancer targets.
"Pfizer is pleased to be involved in this partnership, which will marry cutting-edge shRNA technologies with our efforts in cancer genetics and complex tumor models toward the singular goal of identifying and validating novel targets for cancer therapeutics," Bob Abraham, CSO of Pfizer's oncology operations, said in a statement.
Specific terms of the arrangement were not disclosed.